Atreca, Inc. logo

Atreca, Inc.

Atreca is developing a novel class of antibody therapeutics from effective human anti-cancer immune responses and uses the structure of clinically successful anti-cancer immune responses to identify the antibodies, T cell receptors, and targets that are key to successful treatment outcomes.

In 2012, Atreca acquired exclusive licenses to _Immune Repertoire CaptureÓ Technology from Stanford University. This unique technology is an engine for the discovery and development of novel therapeutics, vaccines, and diagnostics.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttps://www.atreca.com
Founded2010
Disease Focus
Development Stage
STOCK CODENon Listed
Address
500 Saginaw Drive,CA,94063-4750
Redwood City
United States
Email
info@atreca.com
Contact Number
+1 650 595 2595

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/atreca-inc” connections=”true” suffix=””]

Atrecas proprietary high throughput Immune Repertoire Capture_ technology profiles a patients immune response at the single-cell level, enabling the identification and generation of functional human antibodies and TCRs without prior knowledge of antigen and enables identification of the molecular targets of an immune response.

In Dec 2014, Atreca entered in a collaboration with Janssen Biotech to apply Atrecas Immune Repertoire Capture technology to autoimmune disease.

In Aug 2017, Atreca, raised $35 Mn in series B funding co-led by new investor Wellington Management Company LLP. Additional participation included new investor Cormorant Asset Management, as well as other new and existing investors.

In Nov 2015, Atreca raised $56 Mn in its Series A funding with investors included the Bill & Melinda Gates Foundation, Mission Bay Capital and GlaxoSmithKline. The proceeds will fund the further development and advancement of the Companys therapeutic antibodies designed to optimize anti-tumor immune responses in synergy with checkpoint inhibitors and immune activators.

In 2012, Atreca received $6 Mn investment funding from Gates Foundation to build infrastructure and develop its technology.